Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024.

Equillium Inc . (NASDAQ:EQ) shares have reached a 52-week low, dipping to $0.52, as the biotechnology firm, currently valued at $23 million, faces a challenging market environment. According to ...

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the completion of an End-of-Phase 1 meeting ...

Equillium is currently enrolling patients in a Phase 2 proof-of-concept study of EQ101 for patients with alopecia areata. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group ...

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis Feb. 06, 2025 8:00 AM ET Equillium, Inc. (EQ) ...